Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSD microdose-assisted meaning-centred psychotherapy for distress in advanced cancer
ACTRN12623000478617Phase 2Suspended
- Sponsor
- The University of Auckland
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lysergide in major depressive disorder (MDD), anxiety disorder and distress (2 arms), sponsored by The University of Auckland. Primary endpoints: Feasibility, Acceptability and 1 more. Started Oct 2023; status: suspended.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)anxiety disorderdistress
Beyond the preview
Go deeper on ACTRN12623000478617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000478617.